During the first half of 2018, four amendments to the legislation on cost-control of drug pricing [of preparations] in Israel were published.  These amendments, some of which were effected immediately, and some of which will be implemented gradually, significantly change the cost-control mechanisms applied to prescription drugs in recent years and are expected to affect the prices of these drugs in the near future.

Click here to read the full update (in Hebrew).